Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | The safety and efficacy of elotuzumab for the treatment of multiple myeloma

Paul Richardson • 11 Jun 2022
EHA 2022
Multiple Myeloma Antibodies Bortezomib Dexamethasone Elotuzumab Lenalidomide
SWOG 1211

In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the safety and efficacy of elotuzumab for the treatment of multiple myeloma, drawing focus on updated results from the SWOG-1211 trial (NCT01668719). Dr Richardson comments on the encouraging survival data observed with the addition of elotuzumab to bortezomib, lenalidomide and dexamethasone (RVd), and further emphasizes the tolerability of this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Paul Richardson

1:35
Novel therapeutic options and quadruplet regimens for newly diagnosed multiple myeloma
Paul Richardson • 29 Sep 2023
2:51
ANCHOR and LIGHTHOUSE trials: melflufen in multiple myeloma
Paul Richardson • 29 Sep 2023
7:24
Session highlights: managing the aging population in myeloma & promising treatment options
Paul Richardson • 29 Sep 2023
2:59
Exploring the potential role of melflufen in myeloma & updates from the LIGHTHOUSE trial
Paul Richardson • 12 May 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals